EUVIMEDEUVIMED entdecken
EditorialKommentar

Toward rational therapy for mantle cell lymphoma

Mark A Murakami iD

Blood · 2023

DOI: 10.1182/blood.2023021817 ↗

Kurz gefasst

Editorial in der Zeitschrift Blood, 2023. Verfasst von Mark A Murakami. Beteiligte Einrichtung: Dana-Farber Cancer Institute. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Lymphoma, B-Cell. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

decreased in vivo repopulating capacity compared with HSCs cultured with young stromal cells.Treatment of mice bearing Fancd2-or Atm-deficient stromal cells, as well as aged mice, with anti-AREG antibody partially corrected the HSC repopulating capacity defect in these animals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellLymphoma, B-CellHumansGain of Function MutationGuanylate CyclaseCARD Signaling Adaptor Proteins

Substanzen

CARD11 protein, humanGuanylate CyclaseCARD Signaling Adaptor Proteins

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute.

ORCID-Profile: Mark A Murakami

Zitieren

APA

Murakami, M. A. (2023). Toward rational therapy for mantle cell lymphoma. Blood. https://doi.org/10.1182/blood.2023021817

Vancouver

Murakami MA. Toward rational therapy for mantle cell lymphoma. Blood. 2023. doi:10.1182/blood.2023021817

BibTeX
@article{Murakami2023,
  author = {Murakami, Mark A},
  title = {Toward rational therapy for mantle cell lymphoma},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2023021817}
}
Kostenlos starten →